Posted by Michael Wonder on 25 Sep 2017
Novartis’ CAR-T drug needs new payment model, says Express Scripts
25 September 2017 - The price of Novartis’ groundbreaking CAR-T therapy is likely to face resistance, with Express Scripts calling for a new payment model for it and other gene therapies.
In a blog post, Steve Miller, chief medical offer at Express Scripts, the largest US pharmacy benefit manager, said the $475,000 price tag for Kymriah (tisagenlecleucel) made it ‘extremely expensive.’
While the blog post stopped short of calling the drug too expensive, Novartis is likely face resistance from Express Scripts and other payers.
